Go Pro
→ They're shrinking your dollars every single month (From American Alternative) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.08
+20.8%		$0.07
$0.03
▼
$0.11
$870K1.5224,404 shs1,060 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$3.18
+9.3%		$3.21
$1.55
▼
$77.10
$668K2.1990,840 shs3.92 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.80%
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-20.25%-6.67%+3.28%+22.81%+5.00%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-29.71%+78.53%-11.42%-31.25%-94.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
BPTSY
Biophytis
$0.25
$0.25
$0.00
▼
$2.08
$586K2.461,154 shsN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.08
+20.8%		$0.07
$0.03
▼
$0.11
$870K1.5224,404 shs1,060 shs
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$3.18
+9.3%		$3.21
$1.55
▼
$77.10
$668K2.1990,840 shs3.92 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+70.80%
BPTSY
Biophytis
0.00%0.00%0.00%0.00%-87.50%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-20.25%-6.67%+3.28%+22.81%+5.00%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-29.71%+78.53%-11.42%-31.25%-94.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
BPTSY
Biophytis
0.00
N/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest AMPE, HEPA, IMCC, and BPTSY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
BPTSY
Biophytis
N/AN/AN/AN/A($16.18) per shareN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
$39.17M0.02N/AN/A($14.81) per share-0.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
BPTSY
Biophytis
-$18.43MN/AN/AN/AN/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%10/14/2026 (Estimated)
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
-$8.10M-$60.66N/AN/AN/A-39.62%-585.96%-58.32%11/16/2026 (Estimated)

Latest AMPE, HEPA, IMCC, and BPTSY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/14/2026N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$200.00-$0.08+$199.92N/AN/AN/A
8/13/2026Q2 2026
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A-$0.34N/A-$9.92N/A$5.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
BPTSY
Biophytis
N/AN/AN/AN/AN/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
BPTSY
Biophytis
N/A
0.41
N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
N/A
0.56
0.46

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
BPTSY
Biophytis
0.05%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
7.68%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
BPTSY
Biophytis
3.70%
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
5.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
61.14 million1.10 millionNo Data
BPTSY
Biophytis
302.35 million338,000N/A
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
IM Cannabis Corp. stock logo
IMCC
IM Cannabis
44210,000195,000Not Optionable

Recent News About These Companies

IM Cannabis Announces Closing of US$1.31 Million Registered Direct Offering of Common Shares
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-announces-closing-of-us1-31-million-registered-direct-offering-of-common-shares-302889629.html
Best Cannabis Stocks To Follow Now - September 22nd
September 24 at 1:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31042764
IM Cannabis Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 23 at 4:01 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302888181.html
IM Cannabis prices $1.31M registered direct offering
September 23 at 12:58 PM  |  msn.comhttps://www.msn.com/en-us/money/economy/im-cannabis-prices-1-31m-registered-direct-offering/ar-AA2cPnaA
IM Cannabis Announces Pricing of US$1.31 Million Registered Direct Offering of Common Shares
September 23 at 8:37 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-announces-pricing-of-us1-31-million-registered-direct-offering-of-common-shares-302887671.html
IM Cannabis Enters Non-Binding Agreement to Acquire 51% of Space Defense Innovations, Operating in the European Tactical UAS Market
September 23 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-enters-non-binding-agreement-to-acquire-51-of-space-defense-innovations-operating-in-the-european-tactical-uas-market-302887568.html
Penny Stocks To Follow Today - September 20th
September 22 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31038115
Best Cannabis Stocks To Follow Today - September 20th
September 22 at 1:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037800
Critical Analysis: Indivior (OTCMKTS:INVVY) & IM Cannabis (NASDAQ:IMCC)
September 21 at 8:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037230
Penny Stocks To Follow Now - September 18th
September 21 at 4:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036246
Top Cannabis Stocks To Watch Now - September 18th
September 21 at 3:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31035754
Cannabis Stocks To Watch Now - September 19th
September 21 at 1:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31035521
Penny Stocks To Consider - September 19th
September 20, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31035082
IM Cannabis Raises US$225,000 of Gross Proceeds in Convertible Note Financing
September 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-raises-us225-000-of-gross-proceeds-in-convertible-note-financing-302868051.html
IM Cannabis Shares Commence Trading on 30:1 Consolidated Basis
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-shares-commence-trading-on-301-consolidated-basis-302862048.html
IM Cannabis Announces Intention to Complete 30:1 Share Consolidation to Support Nasdaq Minimum Bid Price Compliance
August 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-announces-intention-to-complete-301-share-consolidation-to-support-nasdaq-minimum-bid-price-compliance-302854493.html
Could Commercial Focus Be the Key Theme for IM Cannabis (NASDAQ:IMCC) Today?
August 17, 2026  |  kalkinemedia.comK
IM Cannabis Enters into Agreement to Sell IMC Holdings and European- Focused Assets
August 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-enters-into-agreement-to-sell-imc-holdings-and-european--focused-assets-302852768.html
IM Cannabis Corp. Announces Second Quarter and First Half 2026 Financial Results
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-corp-announces-second-quarter-and-first-half-2026-financial-results-302851407.html
IM Cannabis Raises US$250,000 of Gross Proceeds in Convertible Note Financing
August 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/im-cannabis-raises-us250-000-of-gross-proceeds-in-convertible-note-financing-302846158.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 09/23/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Biophytis NASDAQ:BPTSY

$0.25 0.00 (0.00%)
As of 09/23/2026

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.08 +0.01 (+20.79%)
As of 01:46 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

IM Cannabis stock logo

IM Cannabis NASDAQ:IMCC

$3.18 +0.27 (+9.28%)
Closing price 04:00 PM Eastern
Extended Trading
$3.13 -0.05 (-1.57%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas